References

Worldwide threatening prevalence of carbapenem-resistant Pseudomonas aeruginosa

10.1017/s0950268825100332 · 2025 · External reference

Genetic diversity molecular analysis of metallo beta lactamases among imipenem resistant clinical isolates of Pseudomonas aeruginosa from Peshawar, Pakistan

10.12669/pjms.37.7.4303 · External reference

Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial

10.1016/s1473-3099(20)30796-9 · 2021 · External reference

Cefiderocol-based combination therapy for “difficult-to-treat” gram-negative severe infections: real-life case series and future perspectives

10.3390/antibiotics10060652 · 2021 · External reference

Evaluating the susceptibility of MBL carbapenemase-producing Enterobacteriaceae and Pseudomonas spp. to ceftazidime/avibactam plus aztreonam and cefiderocol: a synergy study and susceptibility profile

10.1016/j.mimet.2025.107311 · 2025 · External reference

Sequencing-based methods and resources to study antimicrobial resistance

10.1038/s41576-019-0108-4 · 2019 · External reference

Antibiotic resistance in Pseudomonas aeruginosa—mechanisms, epidemiology and evolution

10.1016/j.drup.2019.07.002 · 2019 · External reference

Personalized inhaled bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa in cystic fibrosis

10.1038/s41591-025-03678-8 · 2025 · External reference

Metallo-β-lactamases: a last frontier for β-lactams?

10.1016/s1473-3099(11)70056-1 · 2011 · External reference

Incidence of hospital-acquired infections due to carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa in critically ill patients in Italy: a multicentre prospective cohort study

10.1186/s13054-025-05266-1 · 2025 · External reference

Genomics and Susceptibility Profiles of Extensively Drug-Resistant Pseudomonas aeruginosa Isolates from Spain

10.1128/aac.01589-17 · 2017 · External reference

Transforming clinical microbiology with bacterial genome sequencing

10.1038/nrg3226 · 2012 · External reference

In vivo development of aztreonam resistance in meropenem-resistant Pseudomonas aeruginosa owing to overexpression of the blaPDC-16

10.1128/spectrum.03080-22 · 2023 · External reference

An improved algorithm to screen for carbapenemase production in Pseudomonas aeruginosa

10.1093/jacamr/dlaf249 · 2026 · External reference

The role of whole genome sequencing in antimicrobial susceptibility testing of bacteria: report from the EUCAST Subcommittee

10.1016/j.cmi.2016.11.012 · 2017 · External reference

Not all carbapenem-resistant Pseudomonas aeruginosa strains are alike: tailoring antibiotic therapy based on resistance mechanisms

10.1097/qco.0000000000001044 · 2024 · External reference

Molecular analysis of metallo-beta-lactamase-producing Pseudomonas aeruginosa in Switzerland 2022–2023

10.1007/s10096-024-04752-8 · 2024 · External reference

Insight into phylogenomic bias of blaVIM-2 or blaNDM-1 dissemination amongst carbapenem-resistant Pseudomonas aeruginosa

10.1016/j.ijantimicag.2023.106788 · 2023 · External reference

Multicenter, prospective validation of a phenotypic algorithm to guide carbapenemase testing in carbapenem-resistant Pseudomonas aeruginosa using the ERACE-PA Global Surveillance Program

10.1093/ofid/ofab617 · 2022 · External reference

In vitro activity of cefiderocol against a global collection of carbapenem-resistant Pseudomonas aeruginosa with a high level of carbapenemase diversity

10.1093/jac/dkad396 · 2024 · External reference

In vivo efficacy and resistance prevention of cefiderocol in combination with ceftazidime/avibactam, ampicillin/sulbactam or meropenem using human-simulated regimens versus Acinetobacter baumannii

10.1093/jac/dkad032 · 2023 · External reference

Making the leap from research laboratory to clinic: challenges and opportunities for next-generation sequencing in infectious disease diagnostics

10.1128/mbio.01888-15 · 2015 · External reference

In vitro dynamics and mechanisms of cefiderocol resistance development in wild-type, mutator and XDR Pseudomonas aeruginosa

10.1093/jac/dkad172 · 2023 · External reference

Impact of chromosomally encoded resistance mechanisms and transferable β-lactamases on the activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa

10.1093/jac/dkae263 · 2024 · External reference

Combating metallo-β-lactamase-producing Pseudomonas aeruginosa: the fractional inhibitory concentration index as a tool to evaluate antibiotic synergy

10.3390/antibiotics14020210 · 2025 · External reference

Limitations of current techniques in clinical antimicrobial resistance diagnosis: examples and future prospects

10.1038/s44259-024-00033-8 · 2024 · External reference

In vitro activity of cefepime-taniborbactam against carbapenemase-producing Enterobacterales and Pseudomonas aeruginosa isolates recovered in Spain

10.1128/aac.02161-21 · 2022 · External reference

The challenge of treating infections caused by metallo-β-lactamase-producing gram-negative bacteria: a narrative review

10.1007/s40265-024-02102-8 · 2024 · External reference

Relebactam restores susceptibility of resistant Pseudomonas aeruginosa and Enterobacterales and enhances imipenem activity against chromosomal AmpC-producing species: analysis of global SMART 2018-2020

10.1186/s12866-023-02864-3 · 2023 · External reference

Epidemiology and characteristics of metallo-β-lactamase-producing Pseudomonas aeruginosa

10.3947/ic.2015.47.2.81 · 2015 · External reference

Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections

10.1128/cmr.00031-19 · 2019 · External reference

Current management strategies of difficult-to-treat resistant Pseudomonas aeruginosa infections

10.1016/j.idc.2025.11.001 · 2026 · External reference

Update on susceptibility testing: genotypic and phenotypic methods

10.1016/j.cll.2020.08.002 · 2020 · External reference

Ceftolozane/tazobactam use and emergence of resistance: a 4-year analysis of antimicrobial susceptibility in Pseudomonas aeruginosa isolates in a tertiary hospital

10.3389/fmicb.2025.1542491 · 2025 · External reference

In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against gram-negative bacteria

10.1128/aac.01454-17 · 2017 · External reference

Prevalence of metallo-β-lactamase-encoding genes among carbapenem-resistant Pseudomonas aeruginosa strains isolated from burn patients in Iran

10.1590/0037-8682-0044-2018 · 2018 · External reference

The rapid carbapenemase detection method (rCDM) for rapid and accurate detection of carbapenemase-producing enterobacteriaceae and Pseudomonas aeruginosa

10.3389/fcimb.2019.00371 · 2019 · External reference

Sublethal ciprofloxacin treatment leads to rapid development of high-level ciprofloxacin resistance during long-term experimental evolution of Pseudomonas aeruginosa

10.1128/aac.00493-13 · 2013 · External reference

Evolved aztreonam resistance is multifactorial and can produce hypervirulence in Pseudomonas aeruginosa

10.1128/mbio.00517-17 · 2017 · External reference

Challenges for accurate susceptibility testing, detection and interpretation of β-lactam resistance phenotypes in Pseudomonas aeruginosa: results from a Spanish multicentre study

10.1093/jac/dks439 · 2013 · External reference

Cefiderocol: systematic review of mechanisms of resistance, heteroresistance and in vivo emergence of resistance

10.3390/antibiotics11060723 · 2022 · External reference

Activity of cefiderocol against Pseudomonas aeruginosa from the USA and Europe (2020–2023) with difficult-to-treat resistance phenotype, including those nonsusceptible to recently developed β-lactam/β-lactamase inhibitor combinations: results from the SENTRY antimicrobial surveillance program

10.1128/spectrum.02079-25 · 2025 · External reference

Efficacy of cefiderocol in combination with xeruborbactam versus taniborbactam against cefiderocol-resistant NDM-producing Pseudomonas aeruginosa

10.1128/aac.00857-25 · 2025 · External reference

Relative inhibitory activities of the broad-spectrum β-lactamase inhibitor xeruborbactam in comparison with taniborbactam against metallo-β-lactamases produced in Escherichia coli and Pseudomonas aeruginosa

10.1128/aac.00991-23 · 2024 · External reference

Challenges and strategies in managing β-lactam-resistant Pseudomonas aeruginosa in China

10.1093/infdis/jiag033 · 2026 · External reference

Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms

10.1128/cmr.00040-09 · 2009 · External reference

Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?

10.1086/338782 · 2002 · External reference

Carbapenem-resistant Enterobacterales, carbapenem resistant organisms, carbapenemase-producing Enterobacterales, and carbapenemase-producing organisms: terminology past its “sell-by date” in an era of new antibiotics and regional carbapenemase epidemiology

10.1093/cid/ciaa122 · 2020 · External reference

In vitro potency of xeruborbactam in combination with multiple β-lactam antibiotics in comparison with other β-lactam/β-lactamase inhibitor (BLI) combinations against carbapenem-resistant and extended-spectrum β-lactamase-producing Enterobacterales

10.1128/aac.00440-23 · 2023 · External reference

Cefiderocol resistance genomics in sequential chronic Pseudomonas aeruginosa isolates from cystic fibrosis patients

10.1016/j.cmi.2022.11.014 · 2023 · External reference

Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance

10.1111/j.1469-0691.2011.03570.x · 2012 · External reference

In vitro activity of cefiderocol against carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa

10.1089/mdr.2023.0090 · 2023 · External reference

VIM-1, VIM-2, and GES-5 carbapenemases among Pseudomonas aeruginosa isolates at a tertiary hospital in Istanbul, Turkey

10.1089/mdr.2016.0012 · 2017 · External reference

Diagnostic algorithm for the detection of carbapenemases and extended-spectrum β-lactamases in carbapenem-resistant Pseudomonas aeruginosa

10.1128/spectrum.03196-24 · 2025 · External reference

Intravenous fosfomycin: a potential good partner for cefiderocol. clinical experience and considerations

10.3390/antibiotics12010049 · 2022 · External reference

Murepavadin: a new antibiotic class in the pipeline

10.1080/14787210.2018.1441024 · 2018 · External reference

The revival of aztreonam in combination with avibactam against metallo-β-lactamase-producing gram-negatives: a systematic review of in vitro studies and clinical cases

10.3390/antibiotics10081012 · 2021 · External reference

New perspectives on antimicrobial agents: cefiderocol

10.1128/aac.02171-20 · 2021 · External reference

Patient outcomes by baseline pathogen resistance phenotype and genotype in CERTAIN-1, a phase 3 study of cefepime-taniborbactam versus meropenem in adults with complicated urinary tract infection

10.1128/aac.00236-24 · 2024 · External reference

Transcriptomic determinants of the response of ST-111 Pseudomonas aeruginosa AG1 to ciprofloxacin identified by a top-down systems biology approach

10.1038/s41598-020-70581-2 · 2020 · External reference

Addressing carbapenemase-producing extensively drug-resistant Pseudomonas aeruginosa: the potential of cefiderocol and ceftazidime/avibactam plus aztreonam therapy

10.1007/s10096-025-05061-4 · 2025 · External reference

Clinical and microbiological features of ceftolozane/tazobactam-resistant Pseudomonas aeruginosa isolates in a university hospital in central Italy

10.1016/j.jgar.2022.07.010 · 2022 · External reference

Combination of aztreonam, ceftazidime-avibactam and amikacin in the treatment of VIM-1 Pseudomonas aeruginosa ST235 osteomyelitis

10.1016/j.ijid.2021.05.085 · 2021 · External reference

Activity of cefepime/zidebactam (WCK 5222) against ‘problem' antibiotic-resistant gram-negative bacteria sent to a national reference laboratory

10.1093/jac/dkab067 · 2021 · External reference

In vitro activity of the ultrabroad-spectrum-beta-lactamase inhibitor QPX7728 against carbapenem-resistant Enterobacterales with varying intrinsic and acquired resistance mechanisms

10.1128/aac.00757-20 · 2020 · External reference

NitroSpeed-carba NP test for rapid detection and differentiation between different classes of carbapenemases in Enterobacterales

10.1128/jcm.00932-20 · 2020 · External reference

Emerging resistance mechanisms to newer β-lactams in Pseudomonas aeruginosa

10.1016/j.cmi.2025.03.013 · 2025 · External reference

High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection

10.1126/science.288.5469.1251 · 2000 · External reference

Pseudomonas aeruginosa antimicrobial susceptibility profiles, resistance mechanisms and international clonal lineages: update from ESGARS-ESCMID/ISARPAE Group

10.1016/j.cmi.2023.12.026 · 2024 · External reference

Whole-genome sequencing of resistance, virulence and regulation genes in extremely resistant strains of Pseudomonas aeruginosa

10.3390/medsci13010006 · 2025 · External reference

Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies

10.1016/j.biotechadv.2018.11.013 · 2019 · External reference

Genomic insights into carbapenem-resistant Pseudomonas aeruginosa (CRPA): resistome and virulome analysis beyond carbapenemases

10.3390/jcm15051683 · 2026 · External reference

Cefiderocol versus standard therapy for hospital-acquired and health-care-associated gram-negative bacterial bloodstream infection (the GAME CHANGER trial): an open-label, parallel-group, randomised trial

10.1016/s1473-3099(25)00469-4 · 2026 · External reference

European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant gram-negative bacilli (endorsed by European society of intensive care medicine)

10.1016/j.cmi.2021.11.025 · 2022 · External reference

Ceftazidime-avibactam plus aztreonam cocktail for the treatment of VIM-producing Pseudomonas aeruginosa infections: good enough to have another?

10.1093/jac/dkaf083 · 2025 · External reference

FIM-1, a new acquired metallo-β-lactamase from a Pseudomonas aeruginosa clinical isolate from Italy

10.1128/aac.01953-12 · 2013 · External reference

Efflux-mediated multiresistance in gram-negative bacteria

10.1111/j.1469-0691.2004.00763.x · 2004 · External reference

Rapid reversal of carbapenemase-producing Pseudomonas aeruginosa epidemiology from blaVIM- to blaNDM-harbouring isolates in a Greek Tertiary Care Hospital

10.3390/antibiotics13080762 · 2024 · External reference

Global epidemiology and clinical outcomes of carbapenem-resistant Pseudomonas aeruginosa and associated carbapenemases (POP): a prospective cohort study

10.1016/s2666-5247(22)00329-9 · 2023 · External reference

From clinical trials to real-world experiences: evidence about cefiderocol use and potential role in empirical therapy

10.1007/s40121-025-01147-w · 2025 · External reference

10.1128/aac.00311-18

10.1128/aac.00311-18 · External reference

Murepavadin activity tested against contemporary (2016–17) clinical isolates of XDR Pseudomonas aeruginosa

10.1093/jac/dky227 · External reference

In vitro activity of cefiderocol against European Pseudomonas aeruginosa and Acinetobacter spp., including isolates resistant to meropenem and recent β-lactam/β-lactamase inhibitor combinations

10.1128/spectrum.03836-23 · 2024 · External reference

Ceftazidime-avibactam plus aztreonam for the treatment of infections by VIM-type-producing gram-negative bacteria

10.1128/aac.00751-22 · 2022 · External reference

Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis

10.1016/s1473-3099(17)30753-3 · 2018 · External reference

Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections

10.1093/cid/ciae403 · 2024 · External reference

Phenotypic detection of carbapenemase-producing organisms from clinical isolates

10.1128/jcm.01140-18 · 2018 · External reference

Infective endocarditis associated with implantable cardiac device by metallo-β-lactamase-producing Pseudomonas aeruginosa, successfully treated with source control and cefiderocol plus imipenem

10.1128/aac.01313-22 · 2023 · External reference

Carbapenemase-producing Pseudomonas aeruginosa—an emerging challenge

10.1080/22221751.2022.2048972 · 2022 · External reference

Phage therapy in people with cystic fibrosis: a systematic review

10.1016/j.ijid.2026.108581 · 2026 · External reference

In vitro activity of ceftazidime, ceftaroline and aztreonam alone and in combination with avibactam against European gram-negative and Gram-positive clinical isolates

10.1016/j.ijantimicag.2014.12.033 · 2015 · External reference

Cefiderocol for the treatment of infections due to metallo-B-lactamase-producing pathogens in the CREDIBLE-CR and APEKS-NP phase 3 randomized studies

10.1093/cid/ciac078 · 2022 · External reference

Diagnosis and management of infections caused by multidrug-resistant bacteria: guideline endorsed by the Italian Society of Infection and Tropical Diseases (SIMIT), the Italian Society of Anti-Infective Therapy (SITA), the Italian Group for Antimicrobial Stewardship (GISA), the Italian Association of Clinical Microbiologists (AMCLI) and the Italian Society of Microbiology (SIM)

10.1016/j.ijantimicag.2022.106611 · 2022 · External reference

Effectiveness and safety of cefiderocol treatment in patients with gram-negative bacterial infections in Spain in the early access programme: results of the PERSEUS study

10.1007/s10096-025-05108-6 · 2025 · External reference

Antimicrobial susceptibility profiles to predict the presence of carbapenemase genes among carbapenem-resistant Pseudomonas aeruginosa isolates

10.1128/jcm.02874-20 · 2021 · External reference

Resistance to ceftazidime–avibactam and other new β-lactams in Pseudomonas aeruginosa clinical isolates: a multi-center surveillance study

10.1128/spectrum.04266-23 · 2024 · External reference

Cefepime-taniborbactam: ushering in the era of metallo-β-lactamase inhibition

10.1002/phar.70036 · 2025 · External reference

Loss of OprD function is sufficient for carbapenem-resistance-only but insufficient for multidrug resistance in Pseudomonas aeruginosa

10.1186/s12866-025-03935-3 · 2025 · External reference

A large-scale whole-genome comparison shows that experimental evolution in response to antibiotics predicts changes in naturally evolved clinical Pseudomonas aeruginosa

10.1128/aac.01619-19 · 2019 · External reference

In vitro activity of cefiderocol against meropenem-nonsusceptible gram-negative bacilli with defined β-lactamase carriage: SIDERO-WT surveillance studies, 2014–2019

10.1089/mdr.2022.0279 · 2023 · External reference

Mobile carbapenemase genes in Pseudomonas aeruginosa

10.3389/fmicb.2021.614058 · 2021 · External reference

Epidemiological insights into global metallo-β-lactamases-producing Pseudomonas aeruginosa: a comprehensive analysis based on NCBI database

10.1016/j.jgar.2025.05.023 · 2025 · External reference

A comprehensive review of the pathogenic mechanisms of Pseudomonas aeruginosa: synergistic effects of virulence factors, quorum sensing, and biofilm formation

10.3389/fmicb.2025.1619626 · 2025 · External reference